COVID-19 Outpatient Infusion Ordering Criteria/Instructions

HCMC Outpatient Infusion is offering by physician order only monoclonal antibody therapy, bamlanivimab as well casirivimab/imdevimab, for treatment of mild-to-moderate COVID-19 in adults with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.  These treatments are seeing great results for patients in our community who meet criteria.  Below is the ordering criteria for providers:

  1. Facility COVID Casirivimab and Imdevimab Eligibility and Guidance (01.07.2021)
  2. Facility COVID Bamlanivimab Eligibility and Guidance (01.07.2021)